UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 30, 2007

                              ALFACELL CORPORATION
             (Exact name of registrant as specified in its charter)

                                     0-11088
                            (Commission File Number)

          Delaware                                    22-2369085
 (State or other jurisdiction of          (I.R.S. Employer Identification No.)
  incorporation)

               225 Belleville Avenue, Bloomfield, New Jersey 07003
             (Address of principal executive offices, with zip code)

                                 (973) 748-8082
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):

     [ ]  Written communications pursuant to Rule 425 under the Securities Act
          (17 CFR 230.425)

     [ ]  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
          (17 CFR 240.14a-12)

     [ ]  Pre-commencement  communications pursuant to Rule 14d-2(b) under the
          Exchange Act (17 CFR 240.14d-2(b))

     [ ]  Pre-commencement  communications pursuant to Rule 13e-4(c) under the
          Exchange Act (17 CFR 240.13e-4(c))





ITEM 8.01         OTHER EVENTS.

        On January 30, 2007, Alfacell Corporation (the "Company") issued a press
release announcing that the U.S. Food and Drug Administration (FDA) has granted
orphan-drug designation in the United States for the Company's lead drug
candidate, ONCONASE(R) (ranpirnase), for the treatment of malignant
mesothelioma. A copy of the press release is filed as Exhibit 99.1 hereto and
incorporated herein by reference.

ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS.

(c)      Exhibits.

         99.1     Press release of Alfacell Corporation dated January 30, 2007.


                                      -2-



                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      ALFACELL CORPORATION



Date: January 30, 2007                By: /s/ Lawrence A. Kenyon
                                         --------------------------------
                                              Lawrence A. Kenyon
                                              Executive Vice President, Chief
                                              Financial Officer and Secretary



                                      -3-